- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ADA Embraces CV Risk Calculator, Calls for Using GLP-1s Before Insulin in Type 2 Diabetes
The 2019 Standards of Care reflect an ongoing collaboration between the American Diabetes Association and the American College of Cardiology.
The growing connection between treatment for diabetes and management of cardiovascular risk bore more fruit December 17 with the release of the American Diabetes Association (ADA) 2019 Standards of Medical Care in Diabetes, which marked the first the time the chapter on cardiovascular disease management was endorsed by the American College of Cardiology (ACC).
ADA’s new Standards of Care endorse the use of ACC’s and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator Plus, which assesses a person’s 10-year ASCVD risk in people with diabetes.
A separate change updates ADA’s recommendation for injectable medication in patients with type 2 diabetes (T2D): in most cases, those who need additional help lowering glucose should start with glucagon-like peptide-1 (GLP-1) receptor agonists before adding basal insulin or switching to a GLP-1/insulin combination therapy.1
The update comes less than a month after ADA similarly endorsed the cardiologists’ new pathway for patients with T2D and ASCVD. The updated ADA standards feature new language on the role of sodium glucose co-transporter 2 (SGLT2) inhibitors and GLP-1 receptor agonists in T2D care, and the need to consider heart failure in overall diabetes care.2
“For prevention and management of both ASCVD and heart failure, cardiovascular risk factors should be systematically assessed at least annually in all patients with diabetes,” the recommendation states. The ADA document notes that risk scores and biomarkers have been developed for secondary prevention, which could help identify patients who could be candidates for lipid-lowering therapies.
The changes come as the FDA weighs possible changes to practice-changing cardiovascular outcomes trials, which emerged a decade ago in the wake of concerns about the safety of some classes of glucose-lowering treatments for diabetes. Not only did these trials demonstrate that SGLT2 inhibitors and GLP-1 receptor agonists did not cause heart attacks, strokes, or cardiovascular death, but the studies showed that some treatments offered cardiovascular benefits.
More trials are under way to study additional benefits to patients with heart failure or chronic kidney disease (CKD), and the ADA recommendations address the usefulness of SGLT2 inhibitors and GLP-1 receptor agonists for patients with CKD.
The 2019 Standards of Care also carry forward ADA’s previous statements about the need to make insulin more affordable and the recent joint statement with the European Association for the Study of Diabetes on treatment for hypertension in people with diabetes.
Additional updates discuss diabetes technology, medical nutrition, reducing therapeutic inertia, managing diabetes in overweight youth, and simplifying or scaling back medication for persons with diabetes who 65 years of age or older.
“The latest evidence-based research continues to provide critical information that can optimize treatment options and improve patient outcome and quality of life,” ADA Chief Scientific, Medical and Mission Officer William T. Cefalu, MD, said in a statement, noting the importance of the collaboration with ACC and the alignment of recommendations.
References
- American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019; 42(suppl 1): S90-S102. doi: 10.2337/dc19-S009.
- American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019; 42(suppl 1): S103-S123. doi: 10.2337/dc19-S010.
Exclusive Telemedicine Use Linked to Less Favorable Glycemic Outcomes for T2D Endocrinology Care
December 6th 2023Adults with type 2 diabetes (T2D) undergoing endocrinology care are more likely to experience less favorable hemoglobin A1c improvements if they only use telemedicine compared with patients using in-person care or a mix of both.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
New Study Links Sphingolipids With Palmitic Acid to Increased Risk of Sudden Cardiac Death
November 17th 2023Plasma ceramides and sphingomyelins with palmitic acid were linked to a 34% and 37% increased risk of sudden cardiac death (SCD) per higher SD of log sphingolipid levels, respectively.
Read More
